SecBot SecBot
Biotech Drug Report Generated Oct 26, 2026

ATEBRIOZ

MIRM·Mirum Pharmaceuticals, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Approved and launching October 2026 (US); EU marketing authorization application under EMA review. Label expansion for ages 6-12 targeted via sNDA in H1 2027.
Why 4/10
ATEBRIOZ was FDA-approved on September 25, 2026 for patients aged 12+ with FOP; there is no pending regulatory binary in the next ~12 months. The next catalyst is the sNDA submission for ages 6-12 planned for H1 2027 (more than 6 months away). As an already-approved drug launching commercially, with no imminent make-or-break decision, the impactScore is a default 4, ATEBRIOZ is one of several assets in Mirum's pipeline and Livmarli remains the dominant revenue driver.
Actionable Insight NEUTRAL

The next catalyst is the sNDA submission planned for H1 2027 to expand ATEBRIOZ's label to children aged 6 to <12 years, building on the positive Cohort 2 data announced today. The commercial launch in October 2026 and first quarterly sales disclosure (likely on the Q3 2026 earnings call, Nov 17, 2026) will be the earliest tangible read on adoption. Watch for FDA acceptance of the sNDA and any Priority Review designation, as well as enrollment progress in Cohort 3 (ages 2 to <12).

Price Chart

Loading chart...

Executive Summary

ATEBRIOZ (zilurgisertib, also known as INCB000928) is an oral ALK2 inhibitor approved by the FDA on September 25, 2026 for fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. Developed by Incyte and licensed to Mirum Pharmaceuticals in April 2026, it is the third approved FOP drug after Ipsen's Sohonos (2023) and Regeneron's Pasatru (August 2026). On October 26, 2026, Mirum announced positive PROGRESS Cohort 2 results showing zilurgisertib significantly reduced heterotopic ossification volume in children aged 6-12, supporting an sNDA in H1 2027. ATEBRIOZ is commercializing now (launch expected Oct 2026), but with an ultra-small patient population (~800-1,000 US patients) and two competitors already on the market, it represents a meaningful but not company-defining opportunity within Mirum's broader rare-disease portfolio, which is dominated by Livmarli ($129M Q2 2026 revenue).

How It Works

ATEBRIOZ is a once-daily pill that inhibits the ALK2 receptor, a protein that is overactive in people with FOP (fibrodysplasia ossificans progressiva, also known as 'stone man disease'). In FOP, the body's natural repair system mistakenly turns muscles, tendons, and ligaments into bone. By blocking ALK2, ATEBRIOZ interrupts this abnormal bone-forming pathway at its source, reducing the growth of new unwanted bone outside the skeleton.

Trial Status

FDA approved September 25, 2026 based on PROGRESS Cohort 1 (Phase 2, ages 12+). Cohort 2 (Phase 3, ages 6-12) met primary endpoint with topline positive results announced Oct 26, 2026; sNDA submission planned H1 2027. Cohort 3 (ages 2 to <12) is currently enrolling.

The Two-Sided Case

▲ Bull Case5
First-in-class oral ALK2 inhibitor for FOP addresses a high-unmet-need ultra-rare disease. PROGRESS Cohort 1 data showed near-100% reduction in new heterotopic ossification lesions, supporting FDA approval with Priority Review one day ahead of PDUFA.
Positive PROGRESS Cohort 2 topline data (announced Oct 26, 2026) showed zilurgisertib reduced mean HO lesion volume by -8.09 cm³ vs +9.14 cm³ for placebo (treatment difference -14.0 cm³, p=0.003) and no treated patients developed new lesions. This supports an sNDA for ages 6-12 in H1 2027, expanding the addressable pediatric population.
Strong institutional accumulation: 18 tracked managers added or doubled MIRM positions in Q2 2026, including FMR LLC (+86.7% to $430M), Price T Rowe (+54.6% to $311M), and Capital World Investors (+59.2% to $135M).
Analyst consensus is Strong Buy (19 analysts: 8 strong buy, 11 buy, 1 hold) with a mean price target of ~$153, implying ~84% upside from the current ~$83 share price. At least a dozen major firms rate the stock Buy or Outperform.
Mirum has a diversified rare-disease portfolio: Livmarli (maralixibat) generated $129M in Q2 2026 alone (+46% YoY), and the broader pipeline includes brelovitug (positive Phase 3 AZURE-1 HDV data) and volixibat.
▼ Bear Case4
Ultra-small patient population: FOP affects roughly 800-1,000 patients in the US, capping peak revenue even at ~$750K/year pricing (Citizens analyst estimate per Reuters). Mirum's own estimate of >$200M annual revenue potential is modest for a ~$5.4B market cap company.
Already faces two approved FOP competitors: Ipsen's Sohonos (palovarotene, approved Aug 2023) and Regeneron's Pasatru (garetosmab, approved Aug 2026). Sohonos has had weak commercial uptake (~$24M H1 2026 sales) due to safety concerns, suggesting that FOP market penetration is difficult.
Insider selling: CFO Eric Bjerkholt sold ~$978K in stock on Sept 14, 2026 at ~$98/share, and CEO Christopher Peetz sold shares totaling ~$2.9M via 10b5-1 plans from Aug-Sept 2026 near $98-100, above the current ~$83 price.
Mirum is not yet profitable: Q2 2026 net loss was ~$67M and TTM operating cash burn was ~$227M per some estimates, despite 38% YoY revenue growth. Dilution risk exists if capital needs arise before breakeven, which management projects for 2027.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Mirum Pharmaceuticals, Inc. 8-K MIRM ·Originating report

Sources · 10

Hover a chip for the title
1 ir.mirumpharma.com2 biospace.com3 sec.gov4 fda.gov5 stockanalysis.com6 fiercepharma.com7 trialfriend.com8 ainvest.com9 trialfriend.com10 evicenter.com